Convection enhanced delivery of Rhenium (¹⁸⁶Re) Obisbemeda (¹⁸⁶RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial.

ABSTRACT: Rhenium (¹⁸⁶Re) Obisbemeda (¹⁸⁶RNL), chelated-¹⁸⁶Re encapsulated in nanoliposomes and delivered to brain tumors via convection enhanced delivery (CED), was evaluated in a Phase 1 dose escalation trial (NCT01906385). The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives included safety and tolerability, dose distribution, the overall response rate (ORR), disease-specific progression-free survival (PFS), and overall survival (OS). 21 patients received up to 22.3 mCi ¹⁸⁶RNL over 6 dosing cohorts. Most adverse events (AEs) were unrelated to ¹⁸⁶RNL and the MTD was not reached. Although not predefined outcomes, the mOS and mPFS were 11 and 4 months, respectively, and found to correlate with radiation a

SUBMITTER: Brenner AJ 

PROVIDER: S-EPMC11889265 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature